Personalis (PSNL) stock surged 5.24% in after-hours trading on Tuesday, following a series of positive analyst ratings and a significant price target increase. The company, which specializes in advanced genomics for cancer, saw its shares climb as multiple financial firms reaffirmed their confidence in its potential.

Leading the bullish sentiment, H.C. Wainwright raised its price target on Personalis to $13 from $10, maintaining a Buy rating. The firm's decision came after Personalis received undisclosed positive news, suggesting potential developments that could drive future growth. This substantial increase in the price target indicates a strong vote of confidence in the company's prospects.

Adding to the positive outlook, several other prominent financial institutions maintained their Buy ratings on Personalis stock. Guggenheim and BTIG both reaffirmed their Buy ratings, while Morgan Stanley maintained an Equal-Weight stance. This consensus among analysts suggests a generally optimistic view of the company's future performance and market position.